Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021
BackgroundThyroid cancer (TC) is a prevalent malignant tumor of the endocrine system in China. Current research primarily focuses on clinical diagnosis and treatment as well as underlying mechanisms, lacking epidemiological studies on the burden of the disease in China and worldwide.MethodsThe Globa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1500926/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850117142566928384 |
|---|---|
| author | Ziang Meng Ziang Meng Ti Pan Ti Pan Jingjing Yu Jingjing Yu Chao Shi Chao Shi Xuxu Liu Xuxu Liu Dongbo Xue Dongbo Xue Jing Wang Biao Ma Biao Ma |
| author_facet | Ziang Meng Ziang Meng Ti Pan Ti Pan Jingjing Yu Jingjing Yu Chao Shi Chao Shi Xuxu Liu Xuxu Liu Dongbo Xue Dongbo Xue Jing Wang Biao Ma Biao Ma |
| author_sort | Ziang Meng |
| collection | DOAJ |
| description | BackgroundThyroid cancer (TC) is a prevalent malignant tumor of the endocrine system in China. Current research primarily focuses on clinical diagnosis and treatment as well as underlying mechanisms, lacking epidemiological studies on the burden of the disease in China and worldwide.MethodsThe Global Burden of Disease Study 2021 was utilized to assess the incidence, prevalence, death, and disability-adjusted life years of TC in China and worldwide from 1990 to 2021 using the Joinpoint and R software.ResultsFrom 1990 to 2021, the incidence and prevalence rates of TC in China have been consistently rising, and their growth rates are far higher than the global average. In China, TC usually occurs in patients aged 50-59, and the crude death rate generally increases with age. The burden of death among females has gradually declined, while that among males has continued to increase and surpassed females at the beginning of the 21st century. The burden of TC is heavy among middle-aged and elderly populations and the younger populations is also rapidly rising. The increased number of TC is mainly attributed to epidemiological changes, while the increase of deaths in China is primarily due to aging and population. Additionally, we predict that the age-standardized incidence rate of TC in China will continue to grow slowly over the next decade, while the age-standardized death rate will gradually decline among females and stabilize among males.ConclusionIt is imperative to avoid over-screening and over-treatments for TC. Meanwhile, we should also avoid missing aggressive types of TC that may have an impact on overall survival. Additionally, understanding the mechanisms of metastasis and improving clinical treatments should be prioritized for further investigation. TC remains a significant public health challenge in China, necessitating a careful balance of the cost-benefit ratio. |
| format | Article |
| id | doaj-art-49fabcf1b0c34e28b33957aac1c4a970 |
| institution | OA Journals |
| issn | 1664-2392 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-49fabcf1b0c34e28b33957aac1c4a9702025-08-20T02:36:09ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-12-011510.3389/fendo.2024.15009261500926Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021Ziang Meng0Ziang Meng1Ti Pan2Ti Pan3Jingjing Yu4Jingjing Yu5Chao Shi6Chao Shi7Xuxu Liu8Xuxu Liu9Dongbo Xue10Dongbo Xue11Jing Wang12Biao Ma13Biao Ma14Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaNHC Key Laboratory of Etiology and Epidemiology (National Health Commission of the People’s Republic of China), Harbin Medical University, Harbin, ChinaDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, ChinaBackgroundThyroid cancer (TC) is a prevalent malignant tumor of the endocrine system in China. Current research primarily focuses on clinical diagnosis and treatment as well as underlying mechanisms, lacking epidemiological studies on the burden of the disease in China and worldwide.MethodsThe Global Burden of Disease Study 2021 was utilized to assess the incidence, prevalence, death, and disability-adjusted life years of TC in China and worldwide from 1990 to 2021 using the Joinpoint and R software.ResultsFrom 1990 to 2021, the incidence and prevalence rates of TC in China have been consistently rising, and their growth rates are far higher than the global average. In China, TC usually occurs in patients aged 50-59, and the crude death rate generally increases with age. The burden of death among females has gradually declined, while that among males has continued to increase and surpassed females at the beginning of the 21st century. The burden of TC is heavy among middle-aged and elderly populations and the younger populations is also rapidly rising. The increased number of TC is mainly attributed to epidemiological changes, while the increase of deaths in China is primarily due to aging and population. Additionally, we predict that the age-standardized incidence rate of TC in China will continue to grow slowly over the next decade, while the age-standardized death rate will gradually decline among females and stabilize among males.ConclusionIt is imperative to avoid over-screening and over-treatments for TC. Meanwhile, we should also avoid missing aggressive types of TC that may have an impact on overall survival. Additionally, understanding the mechanisms of metastasis and improving clinical treatments should be prioritized for further investigation. TC remains a significant public health challenge in China, necessitating a careful balance of the cost-benefit ratio.https://www.frontiersin.org/articles/10.3389/fendo.2024.1500926/fullthyroid cancerepidemiologyage-period-cohort analysisARIMA modeldisease burdenjoinpoint regression |
| spellingShingle | Ziang Meng Ziang Meng Ti Pan Ti Pan Jingjing Yu Jingjing Yu Chao Shi Chao Shi Xuxu Liu Xuxu Liu Dongbo Xue Dongbo Xue Jing Wang Biao Ma Biao Ma Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 Frontiers in Endocrinology thyroid cancer epidemiology age-period-cohort analysis ARIMA model disease burden joinpoint regression |
| title | Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 |
| title_full | Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 |
| title_fullStr | Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 |
| title_full_unstemmed | Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 |
| title_short | Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021 |
| title_sort | burden of thyroid cancer in china and worldwide from 1990 to 2021 observation comparison and forecast from the global burden of disease study 2021 |
| topic | thyroid cancer epidemiology age-period-cohort analysis ARIMA model disease burden joinpoint regression |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1500926/full |
| work_keys_str_mv | AT ziangmeng burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT ziangmeng burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT tipan burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT tipan burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT jingjingyu burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT jingjingyu burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT chaoshi burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT chaoshi burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT xuxuliu burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT xuxuliu burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT dongboxue burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT dongboxue burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT jingwang burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT biaoma burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 AT biaoma burdenofthyroidcancerinchinaandworldwidefrom1990to2021observationcomparisonandforecastfromtheglobalburdenofdiseasestudy2021 |